RELMADA THERAPEUTICS, INC. - 8-K Filing

Relmada Therapeutics appoints Jørn Skibsted Jakobsen, MD, PhD as Chief Development Officer to lead NDV-01 Phase 3 SPECTRUM program. (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $RLMD

Read the full article at SEC EDGAR

More Regulatory news